What is the recommended acute management and long-term relapse prevention therapy for neuromyelitis optica?

Neuromyelitis Optica: Acute Management and Long-Term Relapse Prevention

Acute Attack Management

For acute NMOSD attacks, treat immediately with high-dose intravenous corticosteroids, and if response is insufficient within 3-5 days, escalate to plasma exchange without delay. 1

First-Line Acute Treatment

• High-dose IV methylprednisolone (typically 1000 mg daily for 3-5 days) is the standard initial therapy for acute relapses 2, 3
• Steroids remain the most common and accessible treatment for acute attacks across all healthcare settings 2

Second-Line Acute Treatment

• Plasma exchange (PLEX) should be initiated promptly if corticosteroids fail to produce adequate clinical improvement 1, 4
• PLEX is particularly effective when started early in the attack course 1
• In the acute setting, 57.6% of patients required plasma exchange in addition to other therapies 5

Emerging Acute Treatment Option

• Complement C5 inhibitors (eculizumab or ravulizumab) show promise as acute attack therapy, particularly for patients with insufficient response to standard treatments 5
• Treatment within 21 days of symptom onset yielded better outcomes (OR 1.58) compared to delayed initiation 5
• In a case series of 33 AQP4-IgG-positive patients, all patients stabilized clinically with C5 inhibition during acute attacks, with good or moderate recovery in 79% 5
• This represents a paradigm shift, as complement inhibitors can potentially halt ongoing complement-mediated astrocyte destruction during active attacks 5

---

Long-Term Relapse Prevention

For AQP4-IgG-positive NMOSD, initiate FDA-approved disease-modifying therapies (eculizumab, ravulizumab, inebilizumab, or satralizumab) as first-line treatment rather than rituximab or traditional immunosuppressants. 6

FDA-Approved First-Line Therapies (AQP4-IgG-Positive)

The three FDA-approved classes demonstrate superior efficacy and safety profiles:

Complement C5 Inhibitors (Preferred Based on Real-World Data)

• Eculizumab or ravulizumab showed the lowest relapse rates (ARR 0,95% CI 0-0.063) and best safety profile in real-world comparative effectiveness studies 6
• C5 inhibitors had significantly lower relapse risk compared to rituximab (HR 0.12,95% CI 0.07-0.24) 6
• Lowest incidence of serious infections (IRR 0.16,95% CI 0.05-0.42 vs rituximab) 6
• Demonstrated efficacy in preventing relapses in phase III trials 2, 7

Anti-CD19 B-Cell Depletion

• Inebilizumab showed significantly lower relapse risk vs rituximab (HR 0.22,95% CI 0.12-0.65) 6
• Targets CD19+ B cells more broadly than rituximab's CD20 targeting 2
• FDA-approved based on phase III trial demonstrating significant relapse reduction 2, 7

IL-6 Receptor Inhibition

• Satralizumab demonstrated lower relapse risk vs rituximab (HR 0.19,95% CI 0.11-0.42) 6
• Can be administered subcutaneously, offering convenience 2
• Effective in phase III trials for AQP4-IgG-positive patients 2, 7

Second-Line Options

Rituximab (Anti-CD20)

• While previously considered standard of care, rituximab carries cumulative risk of relapse, serious infectious adverse events, and treatment-limiting adverse events over time 6
• Should not be used as default first-line given availability of superior FDA-approved alternatives 6
• Remains an option when FDA-approved therapies are unavailable or contraindicated 1, 4

Therapies to Avoid

Mycophenolate mofetil and azathioprine should be avoided given their inferior efficacy and higher adverse event rates. 6

• Azathioprine showed the highest annualized relapse rate (0.34,95% CI 0.18-0.56) and increased composite risk of relapse/SIAE/TLAE (HR 2.33,95% CI 1.08-4.86) compared to rituximab 6
• Mycophenolate mofetil demonstrated increased composite risk (HR 1.75,95% CI 1.02-2.95) compared to rituximab 6

---

Double Seronegative NMOSD (AQP4-IgG and MOG-IgG Negative)

For double seronegative NMOSD, anti-CD20 therapy (rituximab) is the preferred disease-modifying treatment over nonspecific immunosuppressants. 8

• Anti-CD20 therapy showed significantly lower incidence rate ratio (0.02,95% CI 0.01-0.04) and ARR (0.17,95% CI 0.07-0.40) compared to nonspecific immunosuppressants (ARR 0.76,95% CI 0.40-1.43) 8
• B-cell depletion demonstrated prolonged relapse-free intervals in survival analysis 8
• No FDA-approved therapies exist specifically for this population, making anti-CD20 the evidence-based first-line choice 8

---

Special Considerations

Hepatitis Screening

• All NMOSD patients must be screened for hepatitis B and C before initiating immunosuppressive therapy, particularly critical in endemic regions like Taiwan 4

Autologous Hematopoietic Stem Cell Transplantation (AHSCT)

• AHSCT is endorsed only for refractory NMOSD that has failed conventional treatments 9
• The indication has significantly reduced with availability of highly effective monoclonal antibodies 9
• Mixed outcomes reported: progression-free survival 48% at 3-5 years in one registry, but 90% at 5 years in a prospective study using complex protocols 9
• Elimination of AQP4 antibodies post-AHSCT associated with durable remission 9
• Should be considered only in specialized centers for treatment-refractory cases 9

Critical Pitfall

The most common error is defaulting to rituximab or traditional immunosuppressants when FDA-approved NMOSD-specific therapies are available, resulting in preventable relapses and disability accumulation 6.